PD
PDMI.US Paradigm Medical Ind
- Market cap
- USD 32.5K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2012.
Is PDMI.US undervalued?
Graham numberThe Graham number of Paradigm Medical Ind cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Paradigm Medical Ind fundamental analysis
No fundamental analysis for Paradigm Medical Ind yet.
Paradigm Medical Ind stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Paradigm Medical Ind
Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters…
Full company profileParadigm Medical Ind financial statements
2012 annualized: Fiscal year 2012 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2012, the balance sheet is the latest quarter. Figures change when the annual report is published.
Paradigm Medical Ind annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.37M | 3.06M | 3.06M | 2.20M | 2.20M | 1.87M | 1.26M | 858K | 726K | 772K | 578K |
| Gross Profit | 1.16M | 973K | 1.85M | 602K | 918K | 852K | 555K | 450K | 415K | 525K | 376K |
| Operating Income | 11.1M | 3.58M | 392K | 2.18M | 711K | 1.08M | 1.12M | 522K | 834K | 330K | -184K |
| EBITDA | -10.5M | -3.26M | -255K | -2.10M | -680K | -1.16M | -1.12M | -691K | -809K | -325K | - |
| Net Income | -11.2M | -3.16M | 64.0K | -5.39M | -1.82M | -1.73M | -1.73M | -950K | -968K | -474K | -314K |
| EPS | -6,292 | -1,314 | 23 | -1,255 | -103 | -65 | -15 | -0.08 | -0.02 | -0.01 | - |
| Balance Sheet | |||||||||||
| Total Assets | 5.29M | 2.92M | 2.36M | 1.70M | 1.93M | 2.17M | 1.26M | 1.01M | 988K | 895K | 816K |
| Total Liabilities | 2.44M | 2.24M | 1.67M | 3.22M | 3.86M | 4.31M | 5.02M | 4.29M | 3.39M | 3.40M | 3.48M |
| Shareholders' Equity | 2.85M | 680K | 690K | -1.51M | -1.93M | -2.14M | -3.76M | -3.28M | -2.40M | -2.51M | -2.66M |
| Cash & Short-term Investments | 194K | 132K | 131K | 66.0K | 206K | 321K | 27.0K | 55.0K | 51.0K | 27.0K | 9.00K |
| Total Debt | 124K | 117K | 61.0K | 2.05M | 2.66M | 3.04M | 3.85M | 3.11M | 2.51M | 2.19M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.78M | -707K | -477K | -2.67M | -828K | -1.14M | -504K | -498K | -1.21M | -740K | -182K |
| Capital Expenditure | 28.0K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -2.81M | -709K | -477K | -2.67M | -828K | -1.14M | -504K | -498K | -1.21M | -740K | - |
| Ratios | |||||||||||
| ROE | -391.8% | -464.9% | 9.3% | - | - | - | - | - | - | - | - |
| ROA | -210.9% | -108.2% | 2.7% | -316.6% | -94.0% | -79.6% | -137.3% | -94.4% | -98.0% | -53.0% | -38.5% |
| Net Profit Margin | -207.8% | -103.3% | 2.1% | -244.8% | -82.7% | -92.5% | -137.3% | -110.7% | -133.3% | -61.4% | -54.3% |
| Debt to Equity | 0.04x | 0.17x | 0.09x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Paradigm Medical Ind dividends
Paradigm Medical Ind has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Feb 3, 2011.
Who owns Paradigm Medical Ind
Ownership data of Paradigm Medical Ind is not available yet.
Paradigm Medical Ind company profile
- Company name
- Paradigm Medical Ind
- Ticker
- PDMI.US
- Exchange
- USA Stocks
- Listed since
- Jul 10, 1996
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5
- Fiscal year end
- December
- Address
- 4273 South 590 West, Salt Lake City, UT, United States, 84123
- Phone
- 801-977-8970
- Website
- paradigm-medical.com
About Paradigm Medical Ind
Paradigm Medical Industries, Inc. develops, manufactures, sells, and markets medical devices for the early detection of glaucoma and other eye disorders in the United States. The company offers P-2000 biometric analyzer A-scans and P-2500 A-scans/pachymeters; P2700 A/B and P37-II A/B scans; blood flow analyzers for the detection and management of glaucoma and other retinal vascular disorders; P2200 pachymeter and P-2500 A-scan/pachymeters; and LD 500 and LD700 autoperimeters. It also provides corneal topographers, such as PARAVUE 300 for diagnostic and contact lens applications, as well as SURVEYOR 500 for cornea and anterior segment; PARAMAX, which analyzes the functionality of ganglion cells and identifies glaucoma suspects; P60 and P60 ACI ultrasound biomicroscopes; and PARACAM 1000, a non-contact endothelial microscope, as well as software and accessories. The company was founded in 1989 and is based in Salt Lake City, Utah.
Paradigm Medical Ind management
1- Mr. Charles S. PritchardVice President of Sales and Marketing